Long-term safety of spironolactone in acne: Results of an 8-year followup study

Journal of Cutaneous Medicine and Surgery

Volumn 6, Issue 6, 2002, Pages 541-545

  Shaw, James C ^a   White, Lucile E ^b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b MACNEAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; SPIRONOLACTONE;

ACNE; ADULT; ARTICLE; BREAST AUGMENTATION; BREAST TENDERNESS; DIURESIS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HIRSUTISM; HUMAN; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; PRIORITY JOURNAL; QUESTIONNAIRE; VERTIGO;

ACNE VULGARIS; ALDOSTERONE ANTAGONISTS; DATA COLLECTION; DIURESIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MENSTRUATION DISTURBANCES; QUESTIONNAIRES; SAFETY; SPIRONOLACTONE; TIME FACTORS;

EID: 0036872238     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-001-0152-4     Document Type: Article

References (10)

1. Zouboulis CC, Xia L, Akamatsu H, et al. The human sebocyte culture model provides new insights into development and management of seborrhoea and acne. Dermatology 1998; 196:21-31.
2. Shaw JC. Spironolactone in dermatologic therapy. J Am Acad Dermatol 1991; 24:236-243.
3. Shaw JC. Low-dose adjunctive Spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000; 43:498-502.
4. Hughes BR, Cunliffe WJ. Tolerance of Spironolactone. Br J Dermatol 1988; 118:687-691.
5. Lee O, Farquhar C, Toomath R, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2000; (2):CD000194.
6. Loube SD, Quirk RA. Breast cancer associated with administration of Spironolactone [letter] 1975; 1(7922):1428-1429.
7. Danielson DA, Jick H, Hunter JR, et al. Nonestrogenic drugs and breast cancer. Am J Epidemiol 1982; 116:329-332.
8. Friedman GD, Ury HK. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980; 65:723-733.
9. Barker DJP. The epidemiological evidence relating to Spironolactone and malignant disease in man. J Drug Dev 1987; 1(Suppl 2):22-25.
10. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spirono lactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 1984; 111:209-214.